>>Signaling Pathways>> Others>>Trehalose 6-behenate

Trehalose 6-behenate

Catalog No.GC37823

트레할로스 6-베헤네이트는 Th1/Th17 편향 백신 보조제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Trehalose 6-behenate Chemical Structure

Cas No.: 66755-19-9

Size 가격 재고 수량
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Trehalose 6-behenate is a Th1/Th17 skewing vaccine adjuvant. Trehalose 6-behenate (TDB) exerts its effect through binding to the macrophage-inducible C-type lectin Mincle, a pathogen recognition receptor (PRR) that recognises pathogen-associated molecular patterns (PAMPs). The potential of Th1/Th17 skewing adjuvants in vaccine development provides a very real incentive for better definition of the structural motifs required for Mincle binding. Mincle is highly conserved between mice and humans, with 85 % protein similarity. In addition to being a receptor for TDMs, Trehalose 6-behenate (TDB), and the spliceosome-associated protein (SAP)130 (which activates Mincle at a binding site different to that involved in carbohydrate recognition), Mincle is also a receptor for Candida albicans, Malassezia, and Fonsecaea pedrosoi[1].

[1]. Stocker BL, et al. On one leg: trehalose monoesters activate macrophages in a Mincle-dependant manner. Chembiochem. 2014 Feb 10;15(3):382-8.

리뷰

Review for Trehalose 6-behenate

Average Rating: 5 ★★★★★ (Based on Reviews and 1 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Trehalose 6-behenate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.